ELAN Overview

Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is25.50 USD with a low forecast of 22.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Elanco Animal Health Inc revenue for the last quarter amounts to 1.14B USD, increased 12.16

Elanco Animal Health Inc. EPS for the last quarter amounts to -0.57 USD, increased 2750.00

Elanco Animal Health Inc (ELAN) has 9400 emplpoyees as of March 11 2026.

Today ELAN has the market capitalization of 11.66B USD.